Perceptive Advisors LYRA Position
ExitedPerceptive Advisors exited their position in Lyra Therapeutics, Inc. (LYRA) in Q4 2025, after holding the stock for 12 quarters.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
About Lyra Therapeutics, Inc.
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Full company profile →Short Interest
1.1%
0.3 days to cover
Perceptive Advisors LYRA Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Exited | 0 | -229,382 | $0 |
| Q3 2025 | Decreased | 229,382 | -25,768 | $1.5M |
| Q2 2025 | Decreased | 255,150 | -12,502,412 | $2.3M |
| Q1 2025 | Held | 12,757,562 | — | $1.6M |
| Q4 2024 | Held | 12,757,562 | — | $2.6M |
| Q3 2024 | Held | 12,757,562 | — | $3.3M |
| Q2 2024 | Held | 12,757,562 | — | $3.5M |
| Q1 2024 | Held | 12,757,562 | — | $79.4M |
| Q4 2023 | Held | 12,757,562 | — | $66.8M |
| Q3 2023 | Held | 12,757,562 | — | $49.9M |
| Q2 2023 | Increased | 12,757,562 | +3,610,832 | $52.4M |
| Q1 2023 | New | 9,146,730 | +9,146,730 | $18.4M |
Frequently Asked Questions
Does Perceptive Advisors own LYRA?
No. Perceptive Advisors exited their position in Lyra Therapeutics, Inc. (LYRA) in Q4 2025. They previously held the stock for 12 quarters.
How many hedge funds own LYRA?
Based on the 20 specialist biotech hedge funds tracked by BiotechEdge, no tracked fund currently holds an active position in LYRA.
When did Perceptive Advisors first buy LYRA?
Perceptive Advisors's position in LYRA was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Perceptive Advisors's LYRA position increasing or decreasing?
Perceptive Advisors completely exited their LYRA position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
LYRACompany Page →
All fund holders, insider trades, catalysts, and cash runway
Perceptive AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →